Amendment Summary: 27 Updates to the U.S.
Amendment Summary: 27 Updates to the U.S. Constitution
The Constitution of the United States provides two methods for making amendments. Only one has ever been used. The United States Congress can pass a bill setting out a proposed amendment by a vote of two thirds in each body. Or a constitutional convention can be convened by a vote of two thirds of the state legislatures, which will propose one or more amendments. This has never happened and its unclear exactly how such a constitutional convention would operate.
In either case, the amendments to the U.S. Constitution only become effective after being ratified by 3/4 of the states. Some amendments are quickly ratified. The 27th Amendment, on the other hand, was proposed in 1792 and did not achieve final ratification until 1992. Unlike all proposed amendments since Prohibition, this amendment had no deadline.
Some prominent amendments never are ratified. The Equal Rights Amendment was proposed in 1972 and was ratified by 34 of the necessary 38 states. However, advocates could not get the last four states necessary and the Congressionally-imposed deadline for ratification passed.
The first 10 amendments were soon passed and are known collectively as the Bill of Rights. Another cluster of amendments was passed following the Civil War and sought to enshrine the rights of the newly freed slaves.
The United States Constitution now has 25 functioning amendments. There have been 27 ratified in total, but one of these, the 18th, was Prohibition and another, the 21st, was the repeal of Prohibition.
Amendment
1st 1791 Rights to Religion, Speech, Press, Assembly, Petition
2nd 1791 Right to Bear Arms
3rd 1791 Quartering of Soldiers
4th 1791 Search and Seizure
5th 1791 Grand Jury, Double Jeopardy, Self-Incrimination, Due Process
6th 1791 Rights of Accused in Criminal Prosecutions: Rights to Jury Trial, to Confront Opposing Witnesses and to Counsel
7th 1791 Jury Trial
8th 1791 Protections against Excessive Bail, Cruel and Unusual Punishment
9th 1791 Non-Enumerated Rights
10th 1791 Rights Reserved to States
11th 1795 Suits Against a State
12th 1804 Election of President and Vice-President
13th 1865 Abolition of Slavery and Involuntary Servitude
14th 1868 Protects rights against state infringements, defines citizenship, prohibits states from interfering with privileges and immunities, requires due process and equal protection, punishes states for denying vote, and disqualifies Confederate officials and debts
15th 1870 Voting Rights
16th 1913 Federal Income Tax
17th 1913 Popular Election of Senators
18th 1919 Prohibition
19th 1920 Women's Right to Vote
20th 1933 Commencement of Presidential Term and Succession
21st 1933 Repeal of 18th Amendment (Prohibition)
22nd 1951 Two-Term Limitation on President
23rd 1961 District of Columbia Presidential Vote
24th 1964 Abolition of Poll Tax Requirement in Federal Elections
25th 1967 Presidential Vacancy, Disability and Inability
26th 1971 Right to Vote at Age 18
27th 1992 Congressional Compensation
Featured stocks: Coffee Shoppe
For conservative debate: "Keeping it Real"
Game Changing stock $SHMP
Scroll down for more posts ▼
Top 10 Most Recent News Articles
SVRN Aims for New Heights with a Savvy Hire If there’s one thing veteran market-watchers like myself know, it’s that leadership shifts can tell you more about a company’s guts than any press release. SVRN (NASDAQ: SVRN), a name with one foot firmly in the world of digital assets, just snagged Patrick O’Kain for their COO spot. They're not playing around, folks,...
Continue Reading
Midterms and 'Trump Derangement Syndrome': What's the Deal? Every election season there's something new to raise eyebrows, and this time it's 'Trump Derangement Syndrome' (TDS) taking the spotlight. After the dust of the 2026 mid-terms started settling, it turns out there's more than just traditional candidate bickering shaping votes. Can you guess what's driving voters?...
Continue Reading
Strong Q3 Numbers Set the Scene It’s not every day you see a company cough up numbers that speak volumes. Sempra’s third quarter for 2026 paints a picture of solid performance, boasting earnings of $877 million or $1.34 per diluted share per GAAP standards. That’s an eye-opener compared to the paltry $77 million or $0.12 per share they reported same time last year....
Continue Reading
Securities Law Tangles: Coastal Financial Hits a Snag There's no dodging it—Coastal Financial Corporation's dogged by a class action lawsuit, and investors need to sit up and take notice. This kind of legal fracas can hit the stock price like a brick through a window, especially when alleged securities law violations crop up. DJS Law Group's got the reins on this one,...
Continue Reading
Shuffling Pieces in Healthcare Management Change is constant in healthcare management, folks, and it's all about finding the right puzzle pieces. That's what Assembly Health has done by welcoming Grant Davis as their new Chief Experience Officer (CXO). Yeah, you heard me right. It's not a CEO or a CFO, but the CXO role that's under the spotlight this time around, aiming...
Continue Reading
Brooklyn's Gem: MAURE Turns Three Over in Brooklyn, there's a brand bubbling with style called MAURE. Now, we're talking three years strong, surviving the wild bout of the retail scene with a firm two feet planted in home and gifting. The Vision Turned Reality When Maureen Cavalieri, a hospitality veteran since 2009, first tossed this spark into the wind in 2023, it...
Continue Reading
Pushing the Horizons in Hematological Research From the bustling streets of Shanghai to the global stage of the ASH 2026, Dizal has made its mark again. This year's presentations could very well shake up the hematological landscape, showcasing new possibilities for treatment strategies. Golidocitinib: A Game-Changer? Now here's a ticket we've been watching with some high...
Continue Reading
Pardon my skepticism, but when a roofing company names itself Life of Abundance, you know they're aiming to hit it big or at least make you think they're onto something special. LOA Roofing and Construction, holding its ground as a major player in the Central Texas market, set the stage for more ambitious growth. And they found themselves a dance partner in Southstone...
Continue Reading
SKF's Green Initiative: A Major Step Forward You ever find yourself in a room full of big players, each trying to outdo the other? That's the stage set for SKF at COP31, where they're not just strutting around showing off but actually offering some substance—a rarity in these highbrow gatherings. They're juicing up the talk around energy efficiency and circularity...
Continue Reading
Unpacking Lilly's Latest Rheumatology Innovations Lilly's taking the stage at ACR Convergence 2026 with a potent arsenal of data that’s got folks buzzing. The company’s put the pedal to the metal on understanding the intertwining chords of obesity and rheumatologic conditions, and boy, are they not messing around. Retatrutide: A Triple Threat in the Making Headlining...
Continue Reading
Top 5 Most Recently Viewed Articles
SKYX Technologies' Corporate Developments SKYX Technologies, also known as SKYX (NASDAQ: SKYX), is taking significant strides in the smart technology sector. This dynamic company focuses on transforming homes and buildings into smarter, safer, and more advanced spaces. With a remarkable portfolio of over 97 issued and pending patents, SKYX aims to set a new standard in...
Continue Reading
Crinetics Pharmaceuticals Enhances Employee Incentives In a recent announcement, Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX), based in San Diego, revealed a significant step in enhancing employee incentives and strengthening its workforce. On October 10, 2025, the company’s Compensation Committee authorized the granting of stock options and restricted stock units...
Continue Reading
Manulife Investment Management Recognized for Excellence In a significant acknowledgment of its leadership in sustainable finance, Manulife Investment Management (Manulife IM) has made it to the prestigious list of IPE Real Assets' Top 50 Natural Capital Managers. This recognition comes as the firm is gearing up for robust fundraising activities, with an exciting fund...
Continue Reading
Vaxart’s Business Progress and Financial Results Overview Vaxart, Inc. (OTCQX: VXRT), a clinical-stage biotechnology company, recently provided a significant update on its business and reported its financial outcomes for the third quarter of 2025. This latest communication showcases exciting developments in their oral recombinant vaccine platform, which is designed to...
Continue Reading
Madrigal Pharmaceuticals Achieves Enrollment Milestone in NASH Study Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company dedicated to developing innovative therapies for liver diseases, has announced a significant milestone in their MAESTRO-NASH OUTCOMES clinical trial. This study evaluates the efficacy of resmetirom in patients diagnosed with...
Continue Reading